PATENT CLAIM ANALYSIS

Application Number: 16152202
Application Type: Utility
Filing Date: 2018-10
Publication Date: 2019-03
Patent Classification: ["514", "183000"]

Abstract:
Pharmaceuticals compositions comprising the 2S, 4R, ketoconazole enantiomer or its pharmaceutically acceptable salts, hydrates, and solvates, that are substantially free of the 2R, 4S ketoconazole enantiomer are useful to reduce cortisol synthese and for the treatment of type 2 diabetes, hyperglycemia, obesity, insulin resistance, dyslipidemia, hyperlipidemia, hypertension, Metabolic Syndrome, and other diseases and conditions, including but not limited to Cushing's Syndrome, depression, and glaucoma.

Claim (Index 1):
A method for treating a disease or condition associated with elevated cortisol levels in a patient in need of such treatment, said method comprising administering to said patient a dose of from about 50 mg to about 600 mg of a pharmaceutical composition, wherein the pharmaceutical composition comprises a ketoconazole component, wherein at least 90% of the ketoconazole component is the 2S,4R ketoconazole enantiomer.

Metadata:
- Claim Count in Document: 4.0
- Percentile: 97.0
- Lexical Diversity: 1.50909
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15886437', '12443531', '10382186', '13432905', '12504061']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.750342988492898
- 35 USC 102 Novelty (BERT): 0.682380834162604
- Combined Prediction Score: 0.7435467730598686
- Mean Citation Score: 368.459708
- Max Citation Score: 736.9114400000003
- Similarity Product: 666.0273315381338

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test